Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Haas

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Antiviral Therapy|August 9, 2001
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adultsD McMahon, M Lederman, D W Haas, et al.
AIDS (London, England)|December 28, 2000
Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increaseM M Lederman, R McKinnis, D Kelleher, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1992
Yeast casein kinase I homologues: an essential gene pairL C Robinson, E J Hubbard, P R Graves, et al.
Clinical Pharmacology and Therapeutics|February 25, 2014
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 updateM A Martin, J M Hoffman, R R Freimuth, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 2, 2008
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated diseaseJ W Baddley, J R Perfect, R A Oster, et al.
Clinical Pharmacology and Therapeutics|November 4, 2000
Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infectionD W Haas, J Stone, L A Clough, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2001
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapyP G Pappas, J R Perfect, G A Cloud, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Clinical Pharmacology and Therapeutics|September 30, 2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingR S Gammal, M H Court, C E Haidar, et al.
AIDS (London, England)|September 21, 2000
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudineD W Haas, E Arathoon, M A Thompson, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Antiviral Therapy|August 9, 2001
Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adultsD McMahon, M Lederman, D W Haas, et al.
AIDS (London, England)|December 28, 2000
Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increaseM M Lederman, R McKinnis, D Kelleher, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1992
Yeast casein kinase I homologues: an essential gene pairL C Robinson, E J Hubbard, P R Graves, et al.
Clinical Pharmacology and Therapeutics|February 25, 2014
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 updateM A Martin, J M Hoffman, R R Freimuth, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|May 2, 2008
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated diseaseJ W Baddley, J R Perfect, R A Oster, et al.
Clinical Pharmacology and Therapeutics|November 4, 2000
Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infectionD W Haas, J Stone, L A Clough, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2001
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapyP G Pappas, J R Perfect, G A Cloud, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Clinical Pharmacology and Therapeutics|September 30, 2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingR S Gammal, M H Court, C E Haidar, et al.
AIDS (London, England)|September 21, 2000
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudineD W Haas, E Arathoon, M A Thompson, et al.
Pageof 5